Analysis of graft survival in a trial of stem cell transplant in ALS by Tadesse, Tezeta et al.
RESEARCH ARTICLE
Analysis of graft survival in a trial of stem cell transplant in
ALS
Tezeta Tadesse1, Marla Gearing1,2, David Senitzer3, Debra Saxe2, Daniel J. Brat2, Robert Bray2,
Howard Gebel2, Charles Hill2,4, Nicholas Boulis5, Jonathan Riley5, Eva Feldman6, Karl Johe7,
Thomas Hazel7, Meraida Polak1, Jane Bordeau1, Thais Federici2 & Jonathan D. Glass1,2
1Department of Neurology, Emory University School of Medicine, Atlanta, Georgia
2Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
3Histocompatibility Laboratory, City of Hope Cancer Center, Duarte, California
4Molecular Diagnostics Laboratory, Emory University Hospital, Atlanta, Georgia
5Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia
6Department of Neurology, University of Michigan School of Medicine, Ann Arbor, Michigan
7Neuralstem, Inc., Rockville, Maryland
Correspondence
Jonathan D. Glass, 101 Woodruff Circle,
Atlanta, GA 30322. Tel: 404-727-3507;
Fax: 404-778-3495; E-mail: jglas03@emory.edu
Funding Information
This study was funded by Neuralstem, Inc.
and by a grant from the National Institute of
Neurological Disorders and Stroke (R01
NS077982-01; J. D. G., E. L. F., N. M. B.,
and S. B. R.). Additional support was
provided by the ALS Association (E. L. F.) and
grants from NINDS (E. L. F., J. D. G.).
Received: 17 September 2014; Accepted: 20
September 2014
Annals of Clinical and Translational
Neurology 2014; 1(11): 900–908
doi: 10.1002/acn3.134
Abstract
Objective: The first US Food and Drug Administration–approved clinical trial
to treat amyotrophic lateral sclerosis (ALS) with neural stem cell–based therapy
is in progress. The goal of the current study was to identify and assess the sur-
vival of human spinal cord–derived neural stem cells (HSSCs) transplanted into
the spinal cord in patients with ALS. Methods: Spinal cords transplanted with
HSSCs were examined from six autopsy cases. Homogenized tissues were inter-
rogated for the presence of donor versus recipient DNA using real-time PCR
methods (qPCR). Fluorescence in situ hybridization (FISH) was performed
using DNA probes for XY chromosomes to identify male donor HSSCs in one
female case, and immunohistochemistry (IHC) was used to characterize the
identified donor cells. Results: Genomic DNA from donor HSSCs was identi-
fied in all cases, comprising 0.67–5.4% of total tissue DNA in patients surviving
196 to 921 days after transplantation. In the one female patient a “nest” of cells
identified on H&E staining were XY-positive by FISH, confirming donor origin.
A subset of XY-positive cells labeled for the neuronal marker NeuN and stem
cell marker SOX2. Interpretation: This is the first study to identify human
neural stem cells transplanted into a human spinal cord. Transplanted HSSCs
survived up to 2.5 years posttransplant. Some cells differentiated into neurons,
while others maintained their stem cell phenotype. This work is a proof of con-
cept of the survival and differentiation of human stems cell transplanted into
the spinal cord of ALS patients.
Introduction
Amyotrophic lateral sclerosis (ALS) is a rare, yet fatal
neurodegenerative disease resulting from progressive
degeneration of upper and lower motor neurons. ALS
patients typically die within 3–5 years from diagnosis due
to respiratory failure. Therapeutic options for ALS are
limited to a single medication and supportive care, thus
driving the search for innovative approaches to slow dis-
ease progression and improve survival.1–4 Our group is
conducting the first US Food and Drug Administration–
approved clinical trial to surgically transplant human
spinal cord–derived stem cells (HSSCs) into the spinal
cord of ALS patients. The details of the rationale, surgical
methods, and phase I results of this trial have been pub-
lished previously.5–8 Briefly, the injection of HSSCs into
the spinal cord is safe, although the efficacy of this
approach is not yet known.
Previous reports from therapeutic trials of intraspinal
injection of stem cells were not able to demonstrate the
presence or localization of cells in living patients due to
the lack of intracellular markers that could be identified
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by imaging.9–12 Similarly, the stem cells used in our trial
were not identifiable during life. This report focuses on
postmortem identification of transplanted cells using
qPCR and, in the one female patient autopsied to date,
fluorescence in situ hybridization (FISH) using XY
markers for the male donor cells.
Subjects and Methods
Subjects
The clinical trial design and initial results are published
previously.5–7 This report focuses on six ALS patients
who came to autopsy. Five males received injections of
HSSCs into the lumbar spinal cord, and one female
received injections into the cervical spinal cord.
Human neural stem cells and surgical
injection into spinal cord
Details of the derivation, viability of the stem cells, and
the clinical trial were described previously.5 Briefly,
human neural stem cells (HSSCs) HSSC NSI-566RSC
(Neuralstem, Inc., Rockville, MD) were derived from a
single source 8-week gestation human fetal spinal cord,
and serially expanded in culture. Of the six autopsy cases
reported here, three patients received five unilateral injec-
tions and two patients received five bilateral injections
(total 10) spaced 4 mm apart into the lumbar spinal cord
at levels L2–L4. One patient received five unilateral injec-
tions into the cervical spinal cord at levels C3–C5. All
injections contained a suspension of 100,000 cells in
10 lL volume.
Immunosuppression
All patients were placed on immunosuppressive therapy
consisting of prednisone, basiliximab, mycophenolate mo-
fetil, and tacrolimus.5 Tolerance of the immunosuppres-
sive regimen was variable, and five of the six patients
eventually stopped immunosuppressive medications. The
period of time on immunosuppressive medications post-
operatively and prior to death is presented in Table 1.
Spinal cord collection at autopsy
All patients were transported to Emory University Hospi-
tal for autopsy. The entire spinal cord was removed and
the region of injection was identified by the location of
the dural sutures overlying the transplantation field, as
well as the matching of vascular anatomy to images taken
at the time of surgery (see Fig. 2). The region of interest
was cut in 0.5 cm sequential cross-section blocks (“bread
loafed”) and alternate blocks were frozen on dry ice or
fixed for 2–3 days in 4% paraformaldehyde. There were
~20 blocks for each spinal cord, 10 frozen and 10 fixed.
The frozen blocks for each of the six patients were sam-
pled for qPCR analysis by excising a core of anterior and
lateral cord using the back end of a sterile micropipette
tip, and depositing the tissue into a sterile 1.5 mL eppen-
dorf tube. Two core samples were obtained from each
block. The fixed blocks were embedded in paraffin and
sectioned for routine histochemistry (hematoxylin and
eosin stain, Luxol fast blue [LFB] stain), immunohisto-
chemistry (IHC), and FISH.
Quantitative real-time PCR
Using core samples from the frozen blocks of spinal
cord (each block separated by 1 cm) from six patients,
the presence of the genomic DNA sequence unique to
the donor HSSCs NSI-566RSC was determined by qPCR
on the 7500 SDS System (Applied Biosystem, Foster
City, CA). DNA from frozen tissue was extracted using
the QIAamp DNA Mini Kit according to the manufac-
turer’s instructions (Qiagen, Valencia, CA). During the
screening test, a 96-well screening plate (#5002645; Cel-
era, Alameda, CA) containing two sets of 34 chimerism
assays (CA001 to CA034 qPCR primers and fluorescence
probes) plus an additional assay (CA999) were used for









Number of days IM meds
discontinued before death
Survival
days % Donor DNA
1 M U/L 177 165 216 394 0.06–5.40
2 M Bi/L 107 503 67 572 0.18–0.93
3 M Bi/L 259 259 0 259 0.03–2.39
4 M U/L 189 192 133 325 0.07–4.20
5 M U/L 94 283 638 921 0.14–0.67
6 F U/C 139 134 57 196 0.06–0.96
HSSC, human neural stem cells; SC, spinal cord; FK506, tacrolimus; MMF, mycophenolate mofetil; IM, immunomodulatory; U, unilateral; Bi,
bilateral; L, lumbar; C, cervical.
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negative and positive controls. One set was used for the
recipient DNA and one set for the donor DNA. Each
assay well contained a final 25 lL reaction volume of
5 ng of DNA in a 5 lL PCR Master Mix (#5002681;
Celera) containing buffer and DNA polymerase. Recipi-
ent and donor-specific informative markers were identi-
fied by the AlleleSEQR Screening Software, Celera,
Alameda, CA following the PCR. One or more recipi-
ent-specific informative markers (CA001 to CA034,
#5002646 to #5002679; Celera) were then used for quan-
titation. CA999 (#5002680; Celera), the primer/probe set
for RNase P gene, was included as the reference assay.
Each DNA sample was tested at 50–250 ng per reaction.
A pretransplant recipient sample served as a 100%
reference. A total of four PCR reactions were performed:
presample/informative marker, postsample/informative
marker, presample/CA999, and postsample/CA999. Pres-
ample is the recipient’s genomic DNA prior to transplant,
postsample is the genomic DNA extracted from the
spinal cord tissue. Each reaction was run in triplicate and
the mean threshold cycle (CT) was applied in the for-
mula for accurate quantitation. CT is the point on the
qPCR curve where the amplification becomes exponential
and is a relative measure of the target concentration in
the PCR reaction. The calculations were performed by
the AlleleSEQR Quantitation Software based on the rela-
tive quantitation method (2-ΔΔCT). The sensitivity for
detecting DNA chimerism is 0.01–0.1%.
Fluorescence in situ hybridization
One of the six patients was female, while the neural
stem cells were derived from a male donor. Cervical
spinal cord from this patient containing the HSSCs
injection region and noninjection lumbar regions were
embedded in paraffin, sectioned at 4 lm, and mounted
on Superfrost plus slides. Sections were used for dual-
color FISH targeting X and Y chromosomes and pro-
cessed according to the manufacturer’s protocol (Abbott
Molecular, Inc., Des Plaines, IL) at Emory University
Hospital Oncology Cytogenetics Laboratory. CEP X
Spectrum orange (X-chromosome) and Y Spectrum
green (Y-chromosome) direct-labeled fluorescent DNA
probe kit was used (Abbott Molecular). Briefly, slides
were preheated on a hot plate at 56°C overnight, depa-
raffinized three times 5 min each in Americlear, twice in
100% EtOH 1 min each, 0.2 N HCl for 20 min, and
rinsed in dH2O for 3 min. Slides were pretreated using
Pretreatment Reagent (Abbott Molecular) for 30 min at
80°C, rinsed in dH2O for 3 min, and digested in Prote-
ase I (Abbott Molecular) for 40 min at 37°C. Sections
were rinsed in dH2O for 3 min, fixed in 10% buffered
formalin for 10 min, rinsed in dH2O for 3 min, dehy-
drated in a series of graded ethanol (70%, 85%, 100%)
1 min each, and air dried. XY probes were added onto
the sections, covered by coverslip, sealed with rubber
cement, codenatured, and incubated at 37°C for 14–
16 h. Rubber cement and coverslips were removed from
the slides and posthybridization washes were conducted
as follows: preheated 2X SSC/0.3% NP-40 at 72  1°C
for 2 min, air dried, DAPI II (4’,6-Diamidino-2-Pheny-
lindole, Dihydrochloride) (Abbott Molecular, Abbott
Park, Illinois) was added, and sections were re-covered
with coverslips. Slides were stored in the dark at 20°C
overnight before imaging. Fluorescently labeled sections
were analyzed using an Olympus microscope with the
appropriate filters (Olympus, Melville, NY). Images were
captured using CytoVision (Leica Biosystems, Buffalo
Grove, IL). For quantitative analysis, hematoxylin and
eosin (H&E)-stained sections containing nests of putative
stem cells were identified and outlined. Corresponding
regions were marked on FISH sections and 100 cells
each within these regions were counted by two indepen-
dent readers. The percentage of XY- and XX-positive
cells was computed from the total 200 cells counted.
Immunohistochemistry
Formalin-fixed, paraffin-embedded spinal cord sections
(4 lm) were deparaffinized and IHC was performed on
a DAKO Autostainer using antibodies for NeuN (mouse
monoclonal, 1:800; Millipore, Billerica, MA), SOX2 (goat
polyclonal, 1:50; R&D Systems, Minneapolis, MN), glial
fibrillary acidic protein (GFAP) (mouse monoclonal,
1:100; Dako, Carpinteria, CA), OLIG2 (rabbit polyclonal,
1:100; Lifespan Biosciences, Seattle, WA), and LCA
(CD45; monoclonal, 1:640; Dako, Carpinteria, CA) and
costained with hematoxylin. Avidin–biotin–peroxidase
complex was used to detect the antibodies using 3, 30-
diaminobenzidine (DAB) as the chromogen. Standard
positive controls and normal sera without primary anti-
bodies as negative controls were used.
Results
Subject demographics
Demographic data for the six cases, five males and one
female, are presented in Table 1. Five patients received
tacrolimus for 94–259 days and mycophenolate mofetil
for 134–503 days posttransplant. One patient was on both
immunosuppressive drugs until the time of death. Sur-
vival posttransplant surgery ranged from 196 to 921 days.
Patients 1, 4, and 5 received unilateral lumbar injections,
Patients 2 and 3 bilateral lumbar, and Patient 6 unilateral
cervical injections.
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Identification of donor DNA
To assess HSSCs graft survival, the presence of donor
DNA within the recipient spinal cord was measured by
qPCR. Sixteen core samples, eight from each side of the
spinal cord, were analyzed from each case. In all cases,
donor NSI-566RSC DNA was identified in several of the
samples, with maximum percentage of donor DNA in
each case ranging from 0.67% to 5.4% of total DNA
(Fig. 1).
Neuropathology and localization of
transplanted cells
At autopsy, localization of the site of transplant was
accomplished by the presence of dural sutures and match-
ing of the vascular anatomy between intraoperative videos
and postmortem tissue. Gross inspection of the cord sur-
face (Fig. 2A and B) and of the cross sections (Fig. 2C)
did not reveal any tissue disruption, discoloration, or cav-
itation. Indeed, the sites of injection could not be grossly
identified. Each paraffin-embedded block was sectioned
through its entirety and stained with H&E. In three of
the six cases we could identify one or more needle tracks
corresponding to injection sites (Fig. S1). There was
otherwise no tissue disruption, discoloration, or cavitation
of sectioned tissue. In four cases (three male, one female),
we identified “nests” of round cells with little cytoplasm
that did not correspond to normal microanatomy; these
cells did not stain with the GFAP or with the neuronal
precursor protein doublecortin. Representative images
from male Patient 4 spinal cord show histological staining
with H&E (Fig. 2D and G) and LFB (Fig. 2E and H).
IHC shows a lack of labeling with GFAP (Fig. 2F and I).
Based on location and staining properties, these cells were
interpreted to be transplanted HSSCs.
A “nest” of putative HSSCs was identified in one
female patient as previously reported7 and shown in Fig-
ure 3A and B. This region was devoid of GFAP staining
(Fig. 3C). Thus, taking advantage of the gender differ-
ences in male donor HSSCs transplanted in one female
ALS patient, we targeted XY chromosomes for FISH
analysis. Vysis Spectrum orange X probe and Spectrum
green Y probe and counterstained with DAPI were used
for FISH on two regions of the spinal cord – one region
from the HSSCs injection site and one from a noninjected
site that served as a negative control (Fig. S2).
Spinal cord sections from the injection site showed
many XY-chromosome–positive cells within the region
containing the putative HSSCs (Fig. 3D and E). XX-chro-
mosome–positive cells were also noted in close proxim-
ity to XY-chromosome–positive cells (asterisks). Visual
assessment of the DAPI labeling of XY-chromosome–
positive cells showed that the nuclear morphology was
intact and appeared normal with no evidence of conden-
sation or fragmentation. Control sections from the lum-
bar spinal cord, distant from the injection site, showed
exclusively XX-chromosome–positive cells (Fig. S2).
Quantification of randomly selected areas within the
injection site showed 36% XX- and 64% XY-chromo-
some–positive cells, while noninjection site regions had
100% XX-chromosome–positive cells. The female patient
survived 196 days postsurgery demonstrating that many
transplanted HSSCs survived long term. Taken together,
these data demonstrate the identification and survival of
intraspinal transplanted HSSCs into the spinal cord of
ALS patients.
Characterization of transplanted HSSCs
Tissue sections proximate to those demonstrating the
presence of donor cells by FISH were interrogated with
Figure 1. Identification of donor DNA in ALS spinal cord. Schematic diagram showing the presence of donor genomic DNA from spinal cord
autopsy samples in six patients (1–6). Donor genomic DNA was extracted from alternating frozen blocks therefore the distance between each
value is 1 cm. The numbers adjacent to each schematic cord represent the percentage of donor DNA in that tissue homogenate. HSSCs were
unilaterally injected in the lumbar spinal cord in Patients 1, 4, and 5, bilateral lumbar in Patients 2 and 3, and unilateral cervical in Patient 6. The
black bar identifies the region containing the highest percentage of donor DNA, which ranged from 0.67% to 5.4%. ALS, amyotrophic lateral
sclerosis; HSSCs, human spinal cord–derived stem cells.
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antibodies for various cell fate markers and standard
H&E staining (Fig 3F). Sections were stained for the tran-
scription factor SOX2, a marker of multipotent stem cells
in embryos and in adults, NeuN (differentiating neurons),
OLIG2 (developing and differentiated oligodendrocytes),
and GFAP (astrocytes). There were many SOX2-positive
cells in regions of the spinal cord corresponding to the
locations of XY-positive donor cells (Fig. 3G). Visual
analysis of the sections showed many more XY-chromo-
some–positive cells compared to SOX2-positive cells.
There were also NeuN-positive cells located within
regions containing XY-positive donor cells (Fig. 3H).
There was no labeling of OLIG2 suggesting that the
HSSCs did not take on oligodendrocyte fate (data not
shown). There was also no labeling of HSSCs with LCA
(Fig. S4) suggesting the absence of leukocyte infiltration
to the graft region. GFAP labeling was observed through-
out the spinal cord sections, but did not appear to colo-
calize with the XY-positive cells. Thus, there were many
more XY-positive cells than NeuN-positive and SOX2-
positive cells combined, suggesting that transplanted
HSSCs had differentiated beyond stem cell pluripotency
but not to a specific neuronal or glial population.
Discussion
There are three major findings from this autopsy series of
ALS patients undergoing spinal cord transplantation with
HSSCs. First, DNA analysis focused on the regions of trans-
plant identified DNA from donor HSSCs in all patients up
to almost 3 years following surgery. Only one of these
patients tolerated full immunosuppression until the time of
death, suggesting that continuous immunosuppression is
not necessary for continued survival of transplanted cells,
Figure 2. Gross and histological analysis of male ALS spinal cord. Gross image of the spinal cord shows the cord surface at the site of HSSC
transplant (A and B). The vascular anatomy between intraoperative videos (A) corresponds to the postmortem tissue (B). Cross section of the cord
shows no visible tissue disruption (C). Histological staining with H&E (D and G), Luxol fast blue (E and H), and immunohistochemistry for GFAP (F
and I) of 8-lm spinal cord sections from Patient 4 are shown. Nest of putative HSSCs are outlined in D–F. Scale bars: 1 mm (D–F); 50 lm (G–I).
ALS, amyotrophic lateral sclerosis; HSSCs, human spinal cord–derived stem cells; GFAP, glial fibrillary acidic protein.
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though partial rejection cannot be excluded. Second, FISH
analysis using Y-chromosome probes was able to identify
and localize HSSCs in one female patient. Third, immuno-
histochemical labeling of the HSSCs showed evidence of
neuronal differentiation with the expression of NeuN by
some of the XY-positive cells. Other cells continued to
express the stem cell marker SOX2, which is a prominent
marker of these HSSCs prior to transplantation. We did
not see labeling with oligodendrocyte marker OLIG2, and
the astrocyte marker GFAP was difficult to interpret due to
the diffuse expression throughout the spinal cord. How-
ever, there was a focal reduction in GFAP staining identi-
fied in areas of deposition of the transplanted cells (Figs. 2,
3). Taken together, this is the first study showing HSSCs
graft survival and differentiation following transplantation
into human spinal cord.
A critical component to the success of this clinical trial
is the survival of transplanted HSSCs in the spinal cord.
Figure 3. Donor HSSC localization and characterization using XY chromosome FISH and IHC, respectively, in a female ALS patient. H&E staining
shows nests of cells in the female spinal cord (A) (circle). High-power image corresponding to the nest of cells outlined in (A) is shown in (B).
Proximal sections stained with GFAP show lack of labeling of nest of cells (C). FISH labeling shows numerous X (red) Y (green)–positive cells
counterstained with DAPI (blue) (D). Asterisks shows XX–positive recipient cells in the surrounding regions. Inset image from (D) is shown in (E).
Donor HSSCs are positive for XY (solid arrow). H&E labeling of HSSCs graft (arrow) (F) label with SOX2 and (G) and NeuN (H). Scale bars: 1 mm
(A), 50 lm (B–D), 10 lm (E), 100 lm (F–H). HSSC, human spinal cord–derived stem cell; FISH, fluorescence in situ hybridization; IHC,
immunohistochemistry; ALS, amyotrophic lateral sclerosis; GFAP, glial fibrillary acidic protein.
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Our data show that donor HSSC DNA was present 196–
921 days posttransplant survival. Because this is a first-in-
human trial, it is not clear whether immunosuppressive
therapy is necessary for long-term survival of the trans-
planted cells. Interestingly, donor DNA was detected by
qPCR 57–638 days posttransplant after the discontinua-
tion of immunosuppression therapy, and FISH analysis
identified donor cells in situ at 196 days posttransplant.
In this instance, the subject had not been on immunosup-
pressive drugs for 57 days prior to death. We found no
correlation of DNA content to survival period after dis-
continuation of immunosuppressant medications. These
data demonstrate that transplanted HSSCs can survive for
a prolonged period, even in the absence of immunosup-
pression, and raise the interesting question of how long,
if at all, a subject requires immunosuppressive medication
following HSSC transplantation.
The presence of donor DNA using qPCR methods
complimented the histological assessments of HSSC sur-
vival after transplantation. Our H&E staining identified
non-native nests of cells near the injection site in the
spinal cord of three males and one female, which we sus-
pected to be of donor origin.7 In the female patient, XY-
chromosome–positive labeling with FISH confirmed that
the non-native nests of cells were the transplanted HSSCs.
Due to the fact that the H&E labeling identified similar
nests of cells in the male patients, we suspect that all
transplanted ALS patients had successful HSSCs graft sur-
vival. Five of six patients were males, thus limiting our
ability to use FISH analysis to distinguish HSSCs based
on gender. Taken together, this is the first therapeutic
trial localizing HSSCs following intraspinal injection. This
finding is important as it demonstrates that human spinal
cord provides a permissive microenvironment for allogen-
ic fetal-derived transplant and the feasibility of FISH
analysis for future clinical trials.
While the current approach demonstrated the survival of
graft cells, it is difficult to rigorously quantify the percent-
age of grafted cells surviving. Such a measure is relevant to
the question of how much immunosuppression to use and
for how long. It is also relevant to assessing the effectiveness
of the graft. That is, one would expect that the number of
surviving cells would directly impact the therapeutic poten-
tial of the treatment. We have currently begun using iron
oxide nanoparticle loading of donor cells prior to trans-
plantation into large animals. This approach appears not to
perturb cell health or differentiation in vitro. It also allows
for visualization of the grafts to assess surgical accuracy in
the immediate postoperative period. Finally, postmortem
iron staining allows for quantification of graft survival, dis-
tribution, and accuracy (N. N. Boulis, pers. comm. 2014).
The therapeutic concept of cell transplantation into the
spinal cord is based on the idea that these cells may sur-
vive, possibly differentiate, and provide trophic support,
acting as “nurse cells” for endogenous motor neurons.
This concept is supported by preclinical studies in ani-
mals showing that these HSSCs survive, differentiate, and
integrate into the recipient spinal cord environment. In
the SOD1 rat model of ALS these stem cells differentiated
into glial cells and interneurons that functionally inte-
grated into preexisting neural circuitry.13 In these studies,
double labeling with IHC showed 70.4% of the human
nuclear protein (HNu) colabeled with class III b-tubulin
(TUJ1), 19.2% with stem cell marker Nestin, and 1.3%
with GFAP suggesting extensive neuronal differentiation.
In addition, these HSSCs produced glial-derived neuro-
trophic factor (GDNF) and brain-derived neurotrophic
factors (BDNF), which may also provide local trophic
support for motor neurons.13–15 In each of these experi-
mental paradigms there was a positive effect of spinal
cord stem cell transplantation on animal survival.
In this first-in-human study, characterization of HSSCs
transplanted in human ALS spinal cord showed evidence
of neuronal differentiation and maintenance of stem cell
markers. Pretransplant examination of cytospin prepared
donor cells and stained with ICC (immunocytochemistry)
revealed all were positive for SOX2, very few were positive
for OLIG2, and no cells labeled with NeuN (Fig. S3). This
finding is similar to previous work characterizing this
HSSC cell line as 100% SOX1, 93.8% Nestin, 8% bIII-
tubulin, and 0.75% OLIG2-positive cells.16 The one
female patient where donor cells could be identified by
FISH showed populations of transplanted cells that were
labeled with SOX2, suggesting maintenance of the stem
cell properties, and NeuN demonstrating differentiation
into neuronal lineage after transplantation, which is con-
sistent with the data from animal models. Future studies
in human tissue will address the integration of donor cells
into the spinal cord, and their effects on the environment
of endogenous neurons.
In conclusion, this demonstration of survival and dif-
ferentiation of transplanted HSSCs in ALS patients is an
essential positive step to test the potential for therapeutic
efficacy of using HSSCs as neuroprotective and/or neuro-
restorative treatment for ALS and possibly other neurode-
generative disorders.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. H&E staining of a spinal cord section from
Patient 6. Representative images show low and high
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power of needle tracks (arrows) corresponding to the
injection site (A and B).
Figure S2. Fluorescence in situ hybridization (FISH)
staining using DNA probes CEP X Spectrum orange (X
chromosome) and Y Spectrum green (Y chromosome) in
a spinal cord section of a female patient. A “noninjected”
lumbar spinal cord section of the same female patient
that received cervical injections shown in Figure 3 served
as a negative control. H&E staining of the lumbar cord
shows an absence of “nest” of cells (A and B). FISH stain-
ing shows exclusively red XX chromosome labeling count-
erstained with DAPI in all the cells (C, inset i & ii).
Cervical spinal cord section from the “injected” region
shows cells from the central canal with H&E (D), FISH
(E), and a blood vessel (F) with XX chromosome labeling.
These images show the specificity of the XY probe label-
ing shown in Figure 3. Scale bars: 1 mm (A), 50 µm (B–
F), 10 µm (i, ii).
Figure S3. Immunocytochemistry staining of cytospin
prepared HSSC. All the HSSCs show positive staining for
SOX2 (A). There are very few cells (circles) that have
positive staining for OLIG2 (B). There are no NeuN-posi-
tive cells (C).
Figure S4. IHC staining of a cervical spinal cord section
from a female patient. There is no LCA staining in the
“nest” of putative HSSCs (A and B). In the same section,
a blood vessel shows numerous LCA-positive labeling
demonstrating the specificity of the antibody (C).
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